Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The approval is backed by data showing deep, durable responses and manageable tolerability
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The supplements are made using only vegetarian-sourced ingredients
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Subscribe To Our Newsletter & Stay Updated
